LivaNova (NASDAQ:LIVN) Given "Buy" Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of LivaNova (NASDAQ:LIVN - Free Report) in a report issued on Tuesday,Benzinga reports. They currently have a $64.00 price target on the stock.

Several other equities analysts have also recently weighed in on LIVN. Stifel Nicolaus cut their target price on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Mizuho decreased their target price on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 26th. StockNews.com lowered LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Barclays reduced their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Finally, Wolfe Research downgraded LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $59.17.

LivaNova Price Performance

LIVN traded up $0.58 during trading on Tuesday, reaching $44.40. 517,238 shares of the company traded hands, compared to its average volume of 646,354. The company has a market cap of $2.42 billion, a P/E ratio of 105.71 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova has a 12-month low of $32.48 and a 12-month high of $62.04. The firm has a fifty day simple moving average of $38.39 and a 200 day simple moving average of $44.85.

Institutional Investors Weigh In On LivaNova

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV increased its position in shares of LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after purchasing an additional 56,580 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of LivaNova by 0.5% in the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after acquiring an additional 899 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of LivaNova by 2.6% during the 4th quarter. Principal Financial Group Inc. now owns 175,878 shares of the company's stock worth $8,145,000 after purchasing an additional 4,476 shares during the period. Paradice Investment Management LLC grew its holdings in LivaNova by 15.3% during the 4th quarter. Paradice Investment Management LLC now owns 486,821 shares of the company's stock valued at $22,545,000 after purchasing an additional 64,680 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in LivaNova by 122.8% in the 4th quarter. New York State Common Retirement Fund now owns 37,557 shares of the company's stock worth $1,739,000 after purchasing an additional 20,699 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.